CD274 and melanoma: Clinical trials are also underway to evaluate the effectiveness of combined inhibition of BRAF and MEK (MAPK and PI3K-Akt-mTOR signaling pathways) in combination with PD-1/PD-L1 blockade in melanoma [56].